Champions Oncology, Inc.
NASDAQ:CSBRBiotechnology
Healthcare
$4.44 -1.17%
-$0.08 today
- Market cap
- $61.80M
- Beta
- 0.40
- P/E (TTM)
- -41.0
- EPS (TTM)
- -$0.16
52W Low $5.50High $9.63
Volume 0.01M
Average 0.01M
Income Statement
Follow revenue through to earnings.
Revenue
$56.94M
FY 2025 · Annual
+13.5% YoYOperating Income
$4.85M
FY 2025 · Annual
Net Income
$4.70M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Apr 2021 | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Revenue | 41.04M | 49.11M | 53.87M | 50.16M | 56.94M |
| Cost of Revenue | 21.45M | 23.63M | 29.53M | 29.4M | 28.39M |
| Gross Profit | 19.59M | 25.48M | 24.34M | 20.75M | 28.56M |
| Gross Margin | 47.7% | 51.9% | 45.2% | 41.4% | 50.1% |
| Research & Development | 7.2M | 9.37M | 11.55M | 9.54M | 6.83M |
| Selling, General & Admin | 12.03M | 15.5M | 17.24M | 18.13M | 16.88M |
| Operating Expenses | 19.23M | 24.87M | 28.79M | 27.68M | 23.71M |
| Depreciation & Amortization | 1.18M | 1.63M | 2.25M | 1.87M | 1.64M |
| EBITDA | 1.55M | 2.21M | (3.02M) | (5.44M) | 6.27M |
| EBITDA Margin | 3.8% | 4.5% | -5.6% | -10.8% | 11.0% |
| Operating Income | 366K | 607K | (4.45M) | (6.92M) | 4.85M |
| Operating Margin | 0.9% | 1.2% | -8.3% | -13.8% | 8.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 71K | (24K) | (818K) | (387K) | (220K) |
| Income Before Tax | 437K | 583K | (5.27M) | (7.31M) | 4.63M |
| Pre-Tax Margin | 1.1% | 1.2% | -9.8% | -14.6% | 8.1% |
| Income Tax Expense | 75K | 35K | 68K | (32K) | (75K) |
| Net Income | 362K | 548K | (5.34M) | (7.28M) | 4.7M |
| Net Margin | 0.9% | 1.1% | -9.9% | -14.5% | 8.3% |
| EPS (Basic) | 0.03 | 0.04 | (0.39) | (0.54) | 0.34 |
| EPS (Diluted) | 0.02 | 0.04 | (0.39) | (0.54) | 0.33 |
| 13.14M | 13.2M | 13.54M | 13.55M | 13.66M | |
| 14.57M | 14.16M | 13.54M | 13.55M | 14.27M |
CSBR Earnings Waterfall · TTM
NASDAQ:CSBR · Revenue to Net Income
Key Ratios
EPS$-0.16
Gross Margin45.6%
Net Margin-4.5%
P/E Ratio-18.1
P/S Ratio6.6
Analysis
$57.9M of revenue converted into -$2.3M of net income for the selected period. Gross margin is 45.6% and net margin is -4.5%, showing how much revenue survives after costs and taxes. EPS is $-0.16, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 9, 2026 | |
| 8-K | Current report | Oct 16, 2026 |
How much revenue does CSBR generate?
Champions Oncology, Inc. (CSBR) reported $56.94M of revenue in fiscal 2025.
Is CSBR profitable?
Champions Oncology, Inc. (CSBR) reported $4.70M of net income, with a net margin of 8.3%.
Continue the stock analysis
Jump to another research area for this company.